Runner Head: CHEMOTHERAPY AUDIT

Report On a Chemotherapy Audit

[Name of the Institute]

Report On a Chemotherapy Audit

Introduction

Paclitaxel in combination with platinum-based compound (carboplatin or cisplatin) is recommended as an option for second-line (or subsequent) treatment of women with platinum-sensitive or partially platinum-sensitive advanced ovarian cancer, except for women who are allergic to platinumbased compounds.

The introduction of DNA sampling has opened a new era in bio-technology. Modern methods of DNA sequencing are now used for many applications. In medicine and forensic science, DNA sequencing is very important. This is useful in all studies of living organisms, it can provide a good genetic information. Genetic testing of BRCA1 and BRCA2 genes are very useful in predicting cancer. With the advent of such a low cost of testing, the medical field has been extremely useful. However, some issues still exist in the field of genetic testing, and they should be considered for effective testing and reporting. Continued research to improve methods for testing and standardization of various processes in these tests in different countries. In addition, the resources available for such studies are very small at the moment and are working to improve these resources.

Ovarian cancer is the fourth leading cause of cancer death in women, and led to more than 4000 deaths in England and Wales in 2002. Age-standardized incidence rate per 100,000 women in 2000 in England, 17.9 and 20.6 in Wales. The total number of new cases in England and Wales, registered in 2000 was close to 6000. 5-year survival rate is about 30%.

About 80% of ovarian cancers occur in women over the age of 50 years. 5% to 10% of cases occur in women with mutations in BRCA1 or BRCA2, or who have no hereditary polyposis colorectal cancer (HNPCC) gene. Other factors, presumably associated with an increased risk of ovarian cancer include early age at menarche, late menopause, infertility, and the use of drug therapy to improve fertility.

Ovarian cancer is staged surgically according to the International Federation of Gynecology and Obstetrics criteria that stage, I describe tumors confined to the ovaries, stage II describes tumors that spread to the pelvis, stage III describes a tumor that has spread beyond the pelvis and / or involve lymph nodes and stage IV describes a condition in which distant metastasis is detectable. Ovarian cancer is often asymptomatic in the early stages and more than 75% of cases are diagnosed at a late stage of the disease, ie stage III or stage IV disease.

Surgery is usually the first performance are used to treat the disease. However, most women have a complete resection is not possible. Radiation therapy has limited effectiveness and has a negative impact on other abdominal organs.

The majority of patients first-line chemotherapy consists of platinum-based therapy alone or in combination with paclitaxel (where platinum agent or carboplatin or cisplatin).

55% to 75% of women whose tumors respond to first-line therapy relapse within 2 years after completion of treatment. The second line palliative chemotherapy, and aims to reduce symptoms and ...